Patent intelligence · US
US 12258366
Bicyclic heteroaryl compounds and uses thereof
Bicyclic heteroaryl compounds and uses thereof
Patent details — US 12258366
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 25, 2025
- Expiration
- Mar 20, 2045
- Applicant
- Revolution Medicines, Inc.
- Claims
- 14
- CPC classes
- A61K, A61K31/519, A61K31/5377
Quick answer
US 12258366 (Bicyclic heteroaryl compounds and uses thereof) is held by Revolution Medicines, Inc.. Status: granted. Granted Mar 25, 2025. Expires Mar 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Revolution Medicines, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/519, A61K31/5377
More from Revolution Medicines, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12409225
Ras inhibitors
granted -
US 12403196
Ras inhibitors
granted -
US 12384750
Ras inhibitors
granted -
US 12365688
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
granted -
US 12280113
Ras inhibitors
granted -
US 12252497
Ras inhibitors
granted -
US 12202845
Ras inhibitors
granted
Related coverage
Frequently asked questions
What is US patent 12258366?
US 12258366 (Bicyclic heteroaryl compounds and uses thereof) is held by Revolution Medicines, Inc.. Status: granted. Granted Mar 25, 2025. Expires Mar 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12258366?
Revolution Medicines, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 12258366 expire?
Our index shows an expiration date of Mar 20, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.